The success of Sildenafil initially sparked a surge for pharma, nevertheless recent changes present a uncertain outlook for shareholders. Generic versions are eroding profits, and persistent legal battles add further https://lulutxki494421.smblogsites.com/41273224/the-blue-pill-and-pharma-a-volatile-play